Top broker says buy CSL stock while trading on 'cheapest multiple in a long time'

Could the CSL share price go higher?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • CSL is a "recession-proof" stock according to one analyst 
  • CSL reported record plasma collections in the first half of 2023 
  • CSL shares are relatively flat on the market today 

CSL Limited (ASX: CSL) has fallen slightly on the stock market in the last month, but could now be the time to pounce?

CSL shares have descended 0.84% since market close on 4 April and are fetching $290.81 a piece at last look. In today's trade, CSL shares are 0.03% in the red. For perspective, the S&P/ASX 200 Index (ASX: XJO) is rising 0.01% today.

Let's take a look at the outlook for CSL stock going forward.

Two happy scientists analysing test results in a lab

Image source: Getty Images

What's ahead?

CSL is a global biotechnology company that operates a huge plasma collection network along with developing a range of life-saving therapies and vaccines.

CSL is one of multiple "recession-proof" shares according to Airlie Funds Management head of Australian equities Matt Williams.

Williams noted CSL's collection costs are falling and could go down even more. In quotes provided to The Australian, Williams said:

During Covid, the cost of collecting plasma went up significantly. Those costs are
now reducing and in fact, a recession should actually lead to lower collection costs
because they won't have to pay their blood donors as much.

CSL is absolutely in that basket of recession-proof stocks. It's trading on a similar
multiple to Woolworths but it's actually the cheapest multiple I've seen it for a long
time.

CSL reported a net profit of US$1.62 billion in the first half of the 2023 financial year. The company noted plasma collections were at record levels.

Meanwhile, the team at Morgans has also recently placed an add rating on CSL shares with a $337.92 price target. This implies an upside of about 16% based on CSL's current share price.

Analysts are optimistic plasma collections will lift and more people will take the flu vaccine. Morgans said:

A key portfolio holding and key sector pick, we believe CSL is poised to break-out this year, a COVID exit trade, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares offering good value trading around its long-term forward multiple of ~30x.

CSL share price snapshot

The CSL share price has lifted nearly 9% in the last year.

CSL has a market capitalisation of about $140 billion based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor and an elderly couple sit at a desk and look at a lung scan uploaded.
Healthcare Shares

Why did 4DMedical shares charge higher today, then drop?

The company's key technology has received a big tick.

Read more »

Business woman working from home with stock market chart showing percent change on her laptop screen.
Healthcare Shares

Should I invest $10,000 in CSL shares before the end of May?

This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look.

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

Why this fallen ASX 200 blue chip could be a strong buy

I think the market may be underestimating the durability of this healthcare business.

Read more »

Female pharmacist smiles with a digital tablet.
Broker Notes

3 reasons to buy Sigma Healthcare shares today

A leading analyst expects “impressive growth” from Sigma Healthcare shares.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news.
Healthcare Shares

Could this fallen ASX 200 stock be a once-in-a-decade opportunity?

The valuation now looks far more interesting for a healthcare stock with a global leadership position.

Read more »

Hand dropping a mic.
Healthcare Shares

Pro Medicus shares jump as massive US contract win turns heads

Pro Medicus shares are rocketing after a major US win.

Read more »

Two business people shaking hands in an office
Healthcare Shares

Pro Medicus inks $90m contract

Pro Medicus signs a major $90m contract with Beth Israel Lahey Health, boosting its North American growth outlook.

Read more »

Shattered investor with head in hands, with ASX chart in the background.
Healthcare Shares

CSL shares crash, but is a comeback looming?

Has the market become too pessimistic about Australia's biotech giant?

Read more »